1998;43:187–9.7 | CTLA-4 exon 1 position 49 | Controls | 62/47/21 | 0.034 |
HLA DR3 negative controls | 54/36/16 | 0.027 |
2001;48:836–42.9 | HFE H63D polymorphism haplotypes | Iron overload patients | 178/85/60 | 0.001 |
2002;50:520–4.11 | Methylene tetrahydrofolate reductase | Controls | 533/560/114 | 0.053 |
Control, 60 y< | 204/229/34 | 0.005 |
Female colorectal cancer patients | 134/101/35 | 0.031 |
Colorectal cancer stage: Dukes’ B | 94/64/28 | 0.003 |
Colorectal cancer and p53 mutation− | 148/116/39 | 0.036 |
2003;52:547–51.8 | CYPA1A1 exon7 | Controls | 122/22/5 | 0.012 |
EPXH exon 3 | Controls | 59/58/32 | 0.018 |
2003;52:558–62.10 | NOD2 gene 1007fs variant | Crohn’s disease patients | 248/20/3 | 0.017 |